A Longitudinal Analysis of Early Lesion Growth in Presymptomatic Patients with Cerebral Adrenoleukodystrophy

References

1. 1.↵
   2. Moser HW

   . Adrenoleukodystrophy: phenotype, genetics, pathogenesis and therapy. Brain 1997;120:1485–1508 doi:10.1093/brain/120.8.1485

   CrossRefPubMedWeb of Science
2. 2.↵
   2. Huffnagel IC,
   3. Laheji FK,
   4. Aziz-Bose R, et al

   . The natural history of adrenal insufficiency in X-linked adrenoleukodystrophy: an international collaboration. J Clin Endocrinol Metab 2019;104:118–26 doi:10.1210/jc.2018-01307 pmid:30252065

   CrossRefPubMed
3. 3.↵
   2. Moser HW,
   3. Loes DJ,
   4. Melhem ER, et al

   . X-linked adrenoleukodystrophy: overview and prognosis as a function of age and brain magnetic resonance imaging abnormality—a study involving 372 patients. Neuropediatrics 2000;31:227–39 doi:10.1055/s-2000-9236 pmid:11204280

   CrossRefPubMedWeb of Science
4. 4.↵
   2. Liberato AP,
   3. Mallack EJ,
   4. Aziz-Bose R, et al

   . MRI brain lesions in asymptomatic boys with X-linked adrenoleukodystrophy. Neurology 2019;92:e1698–1708 doi:10.1212/WNL.0000000000007294 pmid:30902905

   Abstract/FREE Full Text
5. 5.↵
   2. Loes DJ,
   3. Fatemi A,
   4. Melhem ER, et al

   . Analysis of MRI patterns aids prediction of progression in X-linked adrenoleukodystrophy. Neurology 2003;61:369–74 doi:10.1212/01.wnl.0000079050.91337.83 pmid:12913200

   Abstract/FREE Full Text
6. 6.↵
   2. Melhem ER,
   3. Loes DJ,
   4. Georgiades CS, et al

   . X-linked adrenoleukodystrophy: the role of contrast-enhanced MR imaging in predicting disease progression. AJNR Am J Neuroradiol 2000;21:839–44 pmid:10815658

   Abstract/FREE Full Text
7. 7.↵
   2. Raymond GV,
   3. Aubourg P,
   4. Paker A, et al

   . Survival and functional outcomes in boys with cerebral adrenoleukodystrophy with and without hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2019;25:538–48 doi:10.1016/j.bbmt.2018.09.036 pmid:30292747

   CrossRefPubMed
8. 8.↵
   2. Mallack EJ,
   3. van de Stadt S,
   4. Caruso PA, et al

   . Clinical and radiographic course of arrested cerebral adrenoleukodystrophy. Neurology 2020;94:e2499–2507 doi:10.1212/WNL.0000000000009626 pmid:32482842

   Abstract/FREE Full Text
9. 9.↵
   2. Peters C,
   3. Charnas LR,
   4. DeFor T, et al

   . Cerebral X-linked adrenoleukodystrophy: the University of Minnesota hematopoietic cell transplantation experience from 1991 to 2004. Blood 2004;104:2153 doi:10.1182/blood.V104.11.2153.2153

   CrossRef
10. 10.↵
    2. Miller WP,
    3. Rothman SM,
    4. Nascene D, et al

    . Outcomes after allogeneic hematopoietic cell transplantation for childhood cerebral adrenoleukodystrophy: the largest single-institution cohort report. Blood 2011;118:1971–78 doi:10.1182/blood-2011-01-329235 pmid:21586746

    Abstract/FREE Full Text
11. 11.↵
    2. Miller W,
    3. Bjoraker K,
    4. Charnas L, et al

    . Hematopoietic cell transplantation (HCT) for adrenoleukodystrophy: ten-year experience with 62 patients. Ann Neurol 2010;68:S121 doi:10.1002/ana.22200

    CrossRef
12. 12.↵
    2. Mahmood A,
    3. Raymond GV,
    4. Dubey P, et al

    . Survival analysis of haematopoietic cell transplantation for childhood cerebral X-linked adrenoleukodystrophy: a comparison study. Lancet Neurol 2007;6:687–92 doi:10.1016/S1474-4422(07)70177-1 pmid:17618834

    CrossRefPubMedWeb of Science
13. 13.↵
    2. Pierpont EI,
    3. Nascene DR,
    4. Shanley R, et al

    . Neurocognitive benchmarks following transplant for emerging cerebral adrenoleukodystrophy. Neurology 2020;95:e591–600 doi:10.1212/WNL.0000000000009929 pmid:32616675

    Abstract/FREE Full Text
14. 14.↵
    2. Vogel BH,
    3. Bradley SE,
    4. Adams DJ, et al

    . Newborn screening for X-linked adrenoleukodystrophy in New York State: diagnostic protocol, surveillance protocol and treatment guidelines. Mol Genet Metab 2015;114:599–603 doi:10.1016/j.ymgme.2015.02.002 pmid:25724074

    CrossRefPubMed
15. 15.↵
    2. Loes DJ,
    3. Hite S,
    4. Moser H, et al

    . Adrenoleukodystrophy: a scoring method for brain MR observations. AJNR Am J Neuroradiol 1994;15:1761–66 pmid:7847225

    Abstract/FREE Full Text
16. 16.↵
    2. Musolino PL,
    3. Rapalino O,
    4. Caruso P, et al

    . Hypoperfusion predicts lesion progression in cerebral X-linked adrenoleukodystrophy. Brain 2012;135:2676–83 doi:10.1093/brain/aws206 pmid:22961546

    CrossRefPubMed
17. 17.↵
    2. Pierpont EI,
    3. Eisengart JB,
    4. Shanley R, et al

    . Neurocognitive trajectory of boys who received a hematopoietic stem cell transplant at an early stage of childhood cerebral adrenoleukodystrophy. JAMA Neurol 2017;74:710–17 doi:10.1001/jamaneurol.2017.0013 pmid:28418523

    CrossRefPubMed
18. 18.↵
    2. Moser AB,
    3. Kreiter N,
    4. Bezman L, et al

    . Plasma very long chain fatty acids in 3,000 peroxisome disease patients and 29,000 controls. Ann Neurol 1999;45:100–10 doi:10.1002/1531-8249(199901)45:1<100::AID-ART16>3.0.CO;2-U pmid:9894883

    CrossRefPubMedWeb of Science
19. 19.↵
    2. Eichler F,
    3. Duncan C,
    4. Musolino PL, et al

    . Hematopoietic stem-cell gene therapy for cerebral adrenoleukodystrophy. N Engl J Med 2017;377:1630–38 doi:10.1056/NEJMoa1700554 pmid:28976817

    CrossRefPubMed
20. 20.↵
    2. Jolesz FA

    2. Kikinis R,
    3. Pieper SD,
    4. Vosburgh Kg 3D

    . Slicer a platform for subject-specific image analysis, visualization, and clinical support. In: Jolesz FA, ed. Intraoperative Imaging and Image-Guided Therapy. Springer-Verlag New York; 2014:277–89
21. 21.↵
    2. Egger J,
    3. Kapur T,
    4. Fedorov A, et al

    . GBM volumetry using the 3D slicer medical image computing platform. Sci Rep 2013;3:1364–67 doi:10.1038/srep01364 pmid:23455483

    CrossRefPubMed
22. 22.↵
    2. Mallack EJ,
    3. Turk BR,
    4. Yan H, et al

    . MRI surveillance of boys with X-linked adrenoleukodystrophy identified by newborn screening: meta-analysis and consensus guidelines. J Inherit Metab Dis 2021;44:728–39 doi:10.1002/jimd.12356 pmid:33373467

    CrossRefPubMed
23. 23.↵
    2. Shapiro E,
    3. Krivit W,
    4. Lockman L, et al

    . Long-term effect of bone-marrow transplantation for childhood-onset cerebral X-linked adrenoleukodystrophy. Lancet 2000;356:713–18 doi:10.1016/S0140-6736(00)02629-5 pmid:11085690

    CrossRefPubMedWeb of Science
24. 24.↵
    2. Lebel C,
    3. Beaulieu C

    . Longitudinal development of human brain wiring continues from childhood into adulthood. J Neurosci 2011;31:10937–47 doi:10.1523/JNEUROSCI.5302-10.2011 pmid:21795544

    Abstract/FREE Full Text
25. 25.↵
    2. Aubert-Broche B,
    3. Fonov V,
    4. Narayanan S, et al

    . Canadian Pediatric Demyelinating Disease Network. Onset of multiple sclerosis before adulthood leads to failure of age-expected brain growth. Neurology 2014;83:2140–46 doi:10.1212/WNL.0000000000001045 pmid:25378667

    Abstract/FREE Full Text
26. 26.↵
    2. Tillema JM,
    3. Derks MG,
    4. Pouwels PJ, et al

    . Volumetric MRI data correlate to disease severity in metachromatic leukodystrophy. Ann Clin Transl Neurol 2015;2:932–40 doi:10.1002/acn3.232 pmid:26401514

    CrossRefPubMed
27. 27.↵
    2. Sicotte NL,
    3. Voskuhl RR,
    4. Bouvier S, et al

    . Comparison of multiple sclerosis lesions at 1.5 and 3.0 Tesla. Invest Radiol 2003;38:423–27 doi:10.1097/01.RLI.0000065426.07178.f1 pmid:12821856

    CrossRefPubMedWeb of Science
28. 28.↵
    2. Kothari RU,
    3. Brott T,
    4. Broderick JP, et al

    . The ABCs of measuring intracerebral hemorrhage volumes. Stroke 1996;27:1304–05 doi:10.1161/01.str.27.8.1304 pmid:8711791

    Abstract/FREE Full Text
29. 29.↵
    2. Chang K,
    3. Beers AL,
    4. Bai HX, et al

    . Automatic assessment of glioma burden: a deep learning algorithm for fully automated volumetric and bidimensional measurement. Neuro Oncol 2019;21:1412–22 doi:10.1093/neuonc/noz106 pmid:31190077

    CrossRefPubMed
30. 30.↵
    2. Wattjes MP,
    3. Rovira À,
    4. Miller D, et al

    . MAGNIMS study group. Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis: establishing disease prognosis and monitoring patients. Nat Rev Neurol 2015;11:597–606 doi:10.1038/nrneurol.2015.157 pmid:26369511

    CrossRefPubMed